Regiospecific Synthesis and Anti-Human Immunodeficiency Virus Activity of Novel 5-Substituted <i>N</i>-Alkylcarbamoyl and <i>N,N</i>-Dialkyl Carbamoyl 1,2,3-Triazole-TSAO Analogues

Abstract

Several 5- N-alkyl and 5- N,N-dialkylcarbamoyl substituted analogues of the anti-human immunodeficiency virus (HIV) type 1 lead compound[1-[2‘,5’-bis- O-( tert-butyldimethylsilyl)-β-D-ribofuranosyl]-5-( N,N-dimethylcarbamoyl)-1,2,3-triazole]-3‘-spiro-5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide) have been prepared and evaluated as inhibitors of HIV-1 replication. A new regiospecific synthetic procedure is described. The compounds were prepared by cycloaddition of the appropriate glycosylazide to 2-oxo-alkylidentriphenyl-phosphoranes, followed by treatment with primary or secondary amines, to yield, exclusively, 5-substituted 1,2,3-triazole-TSAO analogues. Several 5-substituted 1,2,3-triazole-TSAO derivatives proved to be potent inhibitors of HIV-1 replication with higher antiviral selectivity than that of the parent TSAO prototype.